PMID- 35855861
OWN - NLM
STAT- MEDLINE
DCOM- 20220721
LR  - 20220728
IS  - 1942-0994 (Electronic)
IS  - 1942-0900 (Print)
IS  - 1942-0994 (Linking)
VI  - 2022
DP  - 2022
TI  - Investigating the Mechanisms of Jieduquyuziyin Prescription Improves Lupus 
      Nephritis and Fibrosis via FXR in MRL/lpr Mice.
PG  - 4301033
LID - 10.1155/2022/4301033 [doi]
LID - 4301033
AB  - Lupus nephritis (LN) is one of the most serious complications of systemic lupus 
      erythematosus (SLE) and one of the leading causes of death. An alternative 
      effective treatment to ameliorate and relieve LN and delay the process of renal 
      tissue fibrosis is urgently needed in the clinical setting. Jieduquyuziyin 
      prescription (JP) has been successfully used to treat SLE, but its potential 
      mechanisms are not sufficiently understood. In this study, we treated MRL/lpr 
      mice with JP for 8 weeks and treated human renal tubular epithelial cells (human 
      kidney 2 (HK-2)) with drug-containing serum to observe the antagonistic effects 
      of JP on inflammation and fibrosis, as well as to investigate the possible 
      mechanisms. Results demonstrated that JP significantly reduced urinary protein 
      and significantly improved pathological abnormalities. Metabolomics combined with 
      ingenuity pathway analysis illustrated that the process of kidney injury in lupus 
      mice may be closely related to farnesoid X receptor (FXR) pathway abnormalities. 
      Microarray biomimetic analysis and LN patients indicated that FXR may play a 
      protective role as an effective therapeutic target for LN and renal fibrosis. JP 
      significantly increased the expression of FXR and inhibited the expression of its 
      downstream targets, namely, nuclear transcription factor kappaB (NF-kappaB) and alpha-smooth 
      muscle actin (alpha-SMA), in the kidney of MRL/lpr mice and HK-2 cells, as confirmed 
      by in vitro and in vivo experiments. In conclusion, JP may mediate the activation 
      of renal FXR expression and inhibit NF-kappaB and alpha-SMA expression to exert 
      anti-inflammatory and antifibrotic effects for LN prevention and treatment.
CI  - Copyright (c) 2022 Jingqun Liu et al.
FAU - Liu, Jingqun
AU  - Liu J
AUID- ORCID: 0000-0003-2524-1364
AD  - The First College of Clinical Medicine, Zhejiang Chinese Medical University, 
      Hangzhou, China.
FAU - Ma, Qing
AU  - Ma Q
AUID- ORCID: 0000-0001-6453-6603
AD  - The First College of Clinical Medicine, Zhejiang Chinese Medical University, 
      Hangzhou, China.
FAU - Sun, Qice
AU  - Sun Q
AUID- ORCID: 0000-0002-8963-6528
AD  - The Second School of Zhejiang Chinese Medical University, 310053, China.
FAU - Luo, Qihan
AU  - Luo Q
AUID- ORCID: 0000-0002-2743-1332
AD  - School of Pharmacy, Zhejiang Chinese Medical University, Hangzhou, China.
FAU - Wang, Yiheng
AU  - Wang Y
AUID- ORCID: 0000-0002-5339-1979
AD  - Academy of Chinese Medical Science, Zhejiang Chinese Medical University, 
      Hangzhou, China.
FAU - Wang, Cheng
AU  - Wang C
AUID- ORCID: 0000-0002-1319-1438
AD  - Academy of Chinese Medical Science, Zhejiang Chinese Medical University, 
      Hangzhou, China.
FAU - Zhu, Akao
AU  - Zhu A
AUID- ORCID: 0000-0002-6394-5592
AD  - The Second Affiliated Hospital of Zhejiang University School of Medicine, 
      Hangzhou, Zhejiang, China.
FAU - Zhao, Lisha
AU  - Zhao L
AUID- ORCID: 0000-0001-6941-5253
AD  - Department of Medicine, Zhejiang Academy of Traditional Chinese Medicine, 
      Hangzhou 310007, China.
FAU - Yin, Lu
AU  - Yin L
AUID- ORCID: 0000-0001-7607-3351
AD  - Department of Pathology, Affiliated Hangzhou First People's Hospital, School of 
      Medicine, Zhejiang University, Hangzhou, China.
FAU - Lou, Jiang
AU  - Lou J
AUID- ORCID: 0000-0002-2927-9709
AD  - Department of Pharmacy, Affiliated Hangzhou First People's Hospital, Zhejiang 
      University School of Medicine, Hangzhou, Zhejiang, China.
FAU - Dong, Yu
AU  - Dong Y
AUID- ORCID: 0000-0003-0177-1678
AD  - Department of Medicine, Zhejiang Academy of Traditional Chinese Medicine, 
      Hangzhou 310007, China.
FAU - Qiu, Ping
AU  - Qiu P
AUID- ORCID: 0000-0003-0104-0082
AD  - School of Pharmacy, Zhejiang Chinese Medical University, Hangzhou, China.
LA  - eng
PT  - Journal Article
DEP - 20220709
PL  - United States
TA  - Oxid Med Cell Longev
JT  - Oxidative medicine and cellular longevity
JID - 101479826
RN  - 0 (Drugs, Chinese Herbal)
RN  - 0 (NF-kappa B)
RN  - 0 (Receptors, Cytoplasmic and Nuclear)
RN  - 0 (jieduquyuziyin)
RN  - 0C5V0MRU6P (farnesoid X-activated receptor)
SB  - IM
MH  - Animals
MH  - *Drugs, Chinese Herbal/administration & dosage
MH  - Humans
MH  - Kidney/metabolism/pathology
MH  - *Lupus Erythematosus, Systemic/drug therapy/metabolism/pathology
MH  - *Lupus Nephritis/drug therapy/metabolism/pathology
MH  - Mice
MH  - Mice, Inbred MRL lpr
MH  - NF-kappa B/metabolism
MH  - Prescriptions
MH  - *Receptors, Cytoplasmic and Nuclear/metabolism
PMC - PMC9288302
COIS- The authors declare that there are no conflicts of interest.
EDAT- 2022/07/21 06:00
MHDA- 2022/07/22 06:00
PMCR- 2022/07/09
CRDT- 2022/07/20 04:07
PHST- 2022/02/21 00:00 [received]
PHST- 2022/05/30 00:00 [revised]
PHST- 2022/06/19 00:00 [accepted]
PHST- 2022/07/20 04:07 [entrez]
PHST- 2022/07/21 06:00 [pubmed]
PHST- 2022/07/22 06:00 [medline]
PHST- 2022/07/09 00:00 [pmc-release]
AID - 10.1155/2022/4301033 [doi]
PST - epublish
SO  - Oxid Med Cell Longev. 2022 Jul 9;2022:4301033. doi: 10.1155/2022/4301033. 
      eCollection 2022.